Merz, Novartis, Pfizer, Sandoz, and Valeant. Arthur Kavanaugh has received grants (or has grants pending) for clinical research from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, and Novartis. April W. Armstrong has received grants (or has grants pending) from AbbVie, Eli Lilly, and Janssen; and has received consulting fees or honoraria from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis, and Pfizer. Abby S. Van Voorhees has received grants (or has grants pending) from AbbVie and Amgen; has received consulting fees or honoraria from Amgen, Aqua, AstraZeneca, Celgene, Dermira, Janssen, LEO Pharma, Novartis, and Pfizer; and has received support for travel to meetings for this study, this manuscript, or other purposes from Celgene. Funding The MAPP survey was sponsored by Celgene Corporation. The authors received editorial support in the preparation of the manuscript from Peloton Advantage, LLC, Jennifer Schwinn, RPh, and Amy Zannikos, PharmD, funded by Celgene Corporation. However, the authors directed and are fully responsible for all content and editorial decisions for this manuscript. Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. References 1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512–6. 2. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol. 2009;60:218–24. 3. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009;60:394–401. 4. Strand V, Sharp V, Koenig AS, et al. Comparison of healthrelated quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis. 2012;71:1143–50. 5. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PLoS One. 2012;7:e52935. 6. Darjani A, Heidarzadeh A, Golchai J, et al. Quality of life in psoriatic patients: a study using the Short Form-36. Int J Prev Med. 2014;5:1146–52. 7. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14–ii17. 8. Boehncke WH, Menter A. Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2013;14:377–88. 9. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69:729–35. 10. Zhu TY, Tam LS, Leung YY, et al. Socioeconomic burden Psoriatic arthritis Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries Clémence Gorlier1, Ana-Maria Orbai2, Déborah Puyraimond-Zemmour1, Laura C Coates3, Uta Kiltz4, Ying-Ying Leung5, Penelope Palominos6, Juan D Cañete7, Rossana Scrivo8, Andra Balanescu9, Emmanuelle Dernis10, Sandra Tälli11, Adeline Ruyssen-Witrand12, Martin Soubrier13, Sibel Zehra Aydin14, Lihi Eder15, Inna Gaydukova16, Ennio Lubrano17, Umut Kalyoncu18, Pascal Richette19,20, M Elaine Husni21, Maarten de Wit22, -0002-8899-9087Josef S Smolen23, Correspondence to Professor Laure Gossec, Hôpital Pitié- Salpêtrière, Service de Rhumatologie, Paris 75013, France; laure.gossec@gmail.comBackground The objective was to compare different definitions of remission and low disease activity (LDA) in patients with psoriatic arthritis (PsA), based on both patients’ and physicians’ perspectives. Methods In ReFlap (Remission/Flare in PsA; NCT03119805), adults with physician-confirmed PsA and >2 years of disease duration in 14 countries were included. Remission was defined as very low disease activity (VLDA), Disease Activity index for PSoriatic Arthritis (DAPSA) ≤4, and physician-perceived and patient-perceived remission (specific question yes/no), and LDA as minimal disease activity (MDA), DAPSA <14, and physician-perceived and patient-perceived LDA. Frequencies of these definitions, their agreement (prevalence-adjusted kappa), and sensitivity and specificity versus patient-defined status were assessed cross-sectionally. Results Of